Management of Opioid Withdrawal After Stopping Oxymorphone

Clinical Presentation and Treatment

The American College of Emergency Physicians recommends initiating buprenorphine in the emergency department to effectively alleviate opioid withdrawal symptoms, combined with symptomatic management using antiemetics and alpha-2 agonists, for patients presenting with classic opioid withdrawal symptoms 2 days after stopping oxymorphone 1, 2
Patients with opioid withdrawal from oxymorphone typically exhibit gastrointestinal symptoms, including abdominal cramping, nausea, vomiting, and decreased appetite, as well as musculoskeletal symptoms like muscle aches 1, 3
The Centers for Disease Control and Prevention notes that pupillary findings, such as pupils equal, round, and reactive to light, are consistent with uncomplicated opioid withdrawal, although dilated pupils are typical in withdrawal 1
The timeline for short-acting opioid withdrawal typically exceeds 12 hours onset, with 48 hours post-cessation being appropriate for initiation of treatment 2

The American College of Emergency Physicians recommends buprenorphine as the most effective treatment for opioid withdrawal and should be administered in the ED, with any DEA-licensed physician able to administer (but not prescribe) buprenorphine in the ED for up to 72 hours without an X-waiver 1, 2
Buprenorphine is superior to clonidine/lofexidine in reducing withdrawal severity, has fewer adverse effects, and patients are more likely to stay in treatment, according to the American Academy of Addiction Psychiatry 2
The Substance Abuse and Mental Health Services Administration confirms that buprenorphine should be administered after confirming the patient is in mild opioid withdrawal to avoid precipitated withdrawal, and for oxymorphone (short-acting), ensuring more than 12 hours since last use 2, 4

The American Society of Addiction Medicine recommends prophylactic antiemetics for patients with opioid-related nausea, with first-line agents including phenothiazines (prochlorperazine 10 mg PO q6h) and dopamine receptor antagonists (metoclopramide 10-20 mg PO or haloperidol 0.5-1 mg PO q6-8h) 4
For nausea persisting despite initial treatment, adding serotonin receptor antagonists (ondansetron) or considering combination therapy with metoclopramide plus ondansetron for synergistic relief is recommended by the National Institute on Drug Abuse 4
Alpha-2 agonists (clonidine or lofexidine) can be used for catecholamine-mediated symptoms if buprenorphine is unavailable or as an adjunct, according to the American College of Emergency Physicians 1, 2

The American Gastroenterological Association advises against using opioid analgesics (morphine, oxycodone, hydromorphone) for chronic visceral abdominal pain in withdrawal, as they perpetuate dependence and risk narcotic bowel syndrome 5
The American College of Emergency Physicians recommends avoiding methadone in the ED setting due to its long duration of action and potential interference with ongoing treatment programs 2
Arranging referral for medication-assisted treatment (MAT) for opioid use disorder is essential when administering buprenorphine under the 72-hour rule, according to the Substance Abuse and Mental Health Services Administration 1, 2